Cardiovascular adverse reactions during antipsychotic treatment: Results of AMSP- A drug surveillance program between 1993 and 2013

Cardiovascular Risk and Diseases

Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial

JAMA Cardiol.

Verma S, Bain SC, Buse JB, Idorn T, Rasmussen S, Ørsted DD, Nauck MA

doi: 10.1001/jamacardio.2019.3080.

Cardiovascular Risk and DiseasesLipid-Lowering Drugs

Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand?

JAMA Cardiol.

Lloyd-Jones DM

doi: 10.1001/

Cardiovascular Risk and DiseasesHeart FailureMyocardial InfarctionThrombosis and Stroke

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)

Circulation.

Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR; CANVAS Program Collaborative Group

doi: 10.1161/CIRCULATIONAHA.

Atrial FibrillationHeart, Artery and Coronary DiseasesHeart Failure

Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension

Eur Heart J.

Rea F, Corrao G, Merlino L, Mancia G

doi: 10.1093/eurheartj/ehy420.

Hypertension

Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A Consensus Paper by the European Myeloma Network and the Italian Society of Arterial Hypertension

J Intern Med.

Bringhen S, Milan A, D'Agostino M, Ferri C, Wäsch R, Gay F, Larocca A, Offidani M, Zweegman S, Terpos E, Goldschmidt H, Cavo M, Ludwig H, Driessen C, Auner H, Caers J, Gramatzki M, Dimopoulos MA, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M

doi: 10.1111/joim.12882.

Further Publications

Cardiovascular Adverse Events With Intravitreal Anti-Vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Clinical Trials

JAMA Ophthalmol

Ngo Ntjam N, Thulliez M, Paintaud G, Salvo F, Angoulvant D, Pisella PJ, Bejan-Angoulvant T

doi: 10.1001/jamaophthalmol.2021.0640

Hypertension

Orthostatic Hypotension, Cardiovascular Outcomes, and Adverse Events: Results From SPRINT

Hypertension.

Juraschek SP, Taylor AA, Wright JT Jr, Evans GW, Miller ER 3rd, Plante TB, Cushman WC, Gure TR, Haley WE, Moinuddin I, Nord J, Oparil S, Pedley C, Roumie CL, Whittle J, Wiggers A, Finucane C, Anne Kenny R, Appel LJ, Townsend RR, SPRINT Research Group

doi: 10.1161/HYPERTENSIONAHA.11.14309.

Myocardial Infarction

Association of Treatment Intensity and Adherence to Lipid-Lowering Therapy with Major Adverse Cardiovascular Events Among Post-MI Patients in Germany

Adv Ther

Ahrens I, Khachatryan A, Monga B, Dornstauder E, Sidelnikov E

doi: 10.1007/s12325-021-01697-8

Atrial Fibrillation

PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial